story of the week
Improved 5-Year Outcomes With Nivolumab Plus Ipilimumab in Advanced Melanoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Five-Year Survival With Combined Nivolumab and Ipilimumab in Advanced Melanoma
N. Engl. J. Med 2019 Sep 28;[EPub Ahead of Print], J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, CL Cowey, D Schadendorf, J Wagstaff, R Dummer, PF Ferrucci, M Smylie, D Hogg, A Hill, I Márquez-Rodas, J Haanen, M Guidoboni, M Maio, P Schöffski, MS Carlino, C Lebbé, G McArthur, PA Ascierto, GA Daniels, GV Long, L Bastholt, JI Rizzo, A Balogh, A Moshyk, FS Hodi, JD WolchokFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.